Cargando…

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment: Erratum

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017253/ https://www.ncbi.nlm.nih.gov/pubmed/31265606 http://dx.doi.org/10.1097/01.md.0000479949.09661.21

Ejemplares similares

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
por: Werner, R.A., et al.
Publicado: (2015)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi, Poupak, et al.
Publicado: (2019)

Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer()
por: Bostan, Ecem, et al.
Publicado: (2022)

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
por: Grande, Enrique, et al.
Publicado: (2013)

Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy
por: Lodish, Maya, et al.
Publicado: (2015)

Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
por: Kim, Mijin, et al.
Publicado: (2020)

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma
por: Matsui, Ai, et al.
Publicado: (2022)

Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018)

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2018)

Selective use of vandetanib in the treatment of thyroid cancer
por: Fallahi, Poupak, et al.
Publicado: (2015)

Erratum: Serum bilirubin as a prognostic marker in patients with acute decompensated heart failure
por: Chintanaboina, Jayakrishna, et al.
Publicado: (2013)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
por: Højer Wang, Linnea, et al.
Publicado: (2023)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
por: Carra, Silvia, et al.
Publicado: (2021)

The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
por: Gawlik, Tomasz, et al.
Publicado: (2010)

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
por: Kreissl, Michael C., et al.
Publicado: (2020)

Erratum to: Prognostic Markers in Peripheral T-Cell Lymphoma
por: Piccaluga, Pier Paolo, et al.
Publicado: (2010)

Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing’s syndrome in a medullary thyroid carcinoma patient
por: Bseiso, Hashem, et al.
Publicado: (2016)

Erratum: Rare case of conus medullaris glioblastoma multiforme in a teenager
Publicado: (2017)

Erratum to “Prognostic Role of Serum Amino Acids in Head and Neck Cancer”
por: Cadoni, Gabriella, et al.
Publicado: (2021)

Erratum to: Evaluation of sHLA-G levels in serum of patients with prostate cancer identify as a potential of tumor marker
por: Heidari, Mohammad Hassan, et al.
Publicado: (2017)

Clinical value of color Doppler ultrasound combined with serum tumor markers for the diagnosis of medullary thyroid carcinoma
por: Yang, Xue, et al.
Publicado: (2021)

Erratum: Correction of Title. Ruptured Conus Medullaris Dermoid Cyst with Fat Droplets in the Central Canal
por: Sharma, Mayur, et al.
Publicado: (2013)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

Serum Spot 14 concentration is negatively associated with thyroid-stimulating hormone level: Erratum
Publicado: (2016)

Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma
por: Park, Hyunju, et al.
Publicado: (2021)

Genetic Alterations in Medullary Thyroid Cancer: Diagnostic and Prognostic Markers
por: A, Taccaliti, et al.
Publicado: (2011)

Erratum: Correction of Affiliations in the Article “Preoperative Prognostic Nutritional Index Is a Prognostic Indicator of Cancer-Specific Survival in Patients Undergoing Endometrial Cancer Surgery”
por: Kim, Yoon Jung, et al.
Publicado: (2023)

The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease: Erratum
Publicado: (2019)

Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
por: Trimboli, Pierpaolo, et al.
Publicado: (2018)

Erratum to: Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with lateral medullary syndrome: case report and literature review
por: Nakano, Hiroto, et al.
Publicado: (2016)

Volumetric and texture analysis of pretherapeutic (18)F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib
por: Werner, Rudolf A., et al.
Publicado: (2018)

Erratum to relationships between serum levels of vitamins and papillary thyroid cancer: a single center case-control study
Publicado: (2023)

Erratum to: Ultrasonography survey and thyroid cancer in the Fukushima Prefecture
por: Jacob, Peter, et al.
Publicado: (2014)

Erratum to “Cell-Type-Dependent Thyroid Hormone Effects on Glioma Tumor Cell Lines”
por: Liappas, Alexandros, et al.
Publicado: (2012)

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
por: Sellam, Jérémie, et al.
Publicado: (2017)

Erratum to: Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer
por: Ryan, Deborah, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a0kvd587jrmns34hsg5igftvf2